Key result
Elevated Lp(a) is linked to ~4.2-fold higher MACE risk after endovascular therapy in PAD.
Why the study?
Does an elevated lipoprotein(a) level (≥30 mg/dL) increase the risk of major adverse cardiovascular events in patients with peripheral artery disease undergoing endovascular therapy?
Cohort (n=138)
No
Does an elevated lipoprotein(a) level (≥30 mg/dL) increase the risk of major adverse cardiovascular events in patients with peripheral artery disease undergoing endovascular therapy?
Answers are grounded in this paper and cite their sources.
In patients with peripheral artery disease undergoing endovascular therapy, elevated lipoprotein(a) (≥30 mg/dL) is an independent predictor of major adverse cardiovascular events, primarily driven by heart failure.
Background: The prognostic value of lipoprotein(a) [Lp(a)] in peripheral artery disease (PAD) remains uncertain. Methods and Results: We retrospectively studied 138 patients with intermittent claudication undergoing endovascular therapy. Patients were classified by Lp(a) level (≥30 vs. <30 mg/dL). The primary endpoint was major adverse cardiovascular events (MACE). Elevated Lp(a) was associated with a higher incidence of MACE (31.1% vs. 9.6%; P=0.002), predominantly driven by heart failure. It independently predicted MACE (HR 4.23) and heart failure (HR 5.12), but not cardiovascular death, myocardial infarction or stroke. Conclusions: Elevated Lp(a) was associated with heart failure-driven MACE after endovascular therapy in patients with PAD.
No takes yet. Share an insight, caveat, or question.
Hoshina et al. (2026) conducted a cohort in Peripheral artery disease with intermittent claudication (n=138). Elevated Lipoprotein(a) (≥30 mg/dL) vs. Low Lipoprotein(a) (<30 mg/dL) was evaluated on Major adverse cardiovascular events (MACE: composite of cardiovascular death, myocardial infarction, stroke, or heart failure) (HR 4.23, 95% CI 1.7-10.3, p=0.002). Elevated lipoprotein(a) (≥30 mg/dL) was independently associated with a higher risk of MACE (31.1% vs. 9.6%; HR 4.23, P=0.002) after endovascular therapy in patients with peripheral artery disease.
Synapse has enriched 10 related papers. Consider them for comparative context: